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Abstract
Selection of novel molecular markers is an important goal of cancer genomics studies. The aim of our
analysis was to apply the multivariate bioinformatical tools to rank the genes – potential markers of
papillary thyroid cancer (PTC) according to their diagnostic usefulness. We also assessed the
accuracyofbenign/malignantclassiﬁcation,basedongeneexpressionproﬁling,forPTC.Weanalyzed
a 180-array dataset (90 HG-U95A and 90 HG-U133A oligonucleotide arrays), which included a
collectionof57PTCs,61benignthyroidtumors,and62apparentlynormaltissues.Geneselectionwas
carriedoutbythesupportvectormachinesmethodwithbootstrapping,whichallowedus1)rankingthe
genesthatweremostimportantforclassiﬁcationqualityandappearedmostfrequentlyintheclassiﬁers
(bootstrap-based feature ranking, BBFR); 2) ranking the samples, and thus detecting cases that were
mostdifﬁculttoclassify(bootstrap-basedoutlierdetection).TheaccuracyofPTCdiagnosiswas98.5%
for a 20-gene classiﬁer, its 95% conﬁdence interval (CI) was 95.9–100%, with the lower limit of CI
exceeding 95% already for ﬁve genes. Only 5 of 180 samples (2.8%) were misclassiﬁed in more than
10% of bootstrap iterations. We speciﬁed 43 genes which are most suitable as molecular markers of
PTC, among them some well-known PTC markers (MET, ﬁbronectin 1, dipeptidylpeptidase 4, or
adenosine A1 receptor) and potential new ones (UDP-galactose-4-epimerase, cadherin 16, gap
junction protein 3, sushi, nidogen, and EGF-like domains 1, inhibitor of DNA binding 3, RUNX1,
leiomodin 1, F-box protein 9, and tripartite motif-containing 58). The highest ranking gene,
metallophosphoesterase domain-containing protein 2, achieved 96.7% of the maximum BBFR score.
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Introduction
Discrimination between benign thyroid nodules and
cancer is an important aspect of determining the optimal
extent of thyroid surgery. Currently, this is achieved by
routine morphologic assessment of cytopathology
samples. However, this method does not allow proper
classiﬁcation of all thyroid tumors (Baloch & Livolsi
2002,Francetal.2003).Atseveralinstitutions,genomic
studies have been undertaken which besides focusing on
basicbiologicalissues(Huangetal.2001,Giordanoetal.
2005), also explore potential diagnostic applications
(Aldred et al. 2004, Chevillard et al. 2004, Finley et al.
2004a,b). Our recent microarray-based analysis brought
a 20-gene classiﬁer to differentiate between papillary
thyroid cancer (PTC) and normal thyroid tissue (Jarzab
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datasets (Eszlinger et al. 2006). Very large and easily
distinguishable differences between the molecular
proﬁles of PTC and normal thyroid have clearly
demonstrated the applicability of gene expression
ﬁndings to diagnostic purposes. However, even more
desirable for the clinician would be genomic proﬁling-
based capability to discriminate between malignant
tumors and various benign lesions. Therefore, we
decided to use a balanced mixture of samples from
malignant and benign tumors and normal thyroid tissue
to mimic the clinical situation, where the material from
any of these may be obtained and shall be properly
classiﬁed. This large 180-array dataset is derived
respectively from de novo studies (nZ40), previously
published own microarray data (nZ124; Eszlinger et al.
2001, 2004, Jarzab et al. 2005), and accessible datasets
published by other authors (nZ16; Huang et al. 2001).
We set the following goals for the study:
1. To assess accuracy of benign/malignant classi-
ﬁcation of thyroid specimens in relation to gene
set size, in the context of PTC and
2. To optimize the list of diagnostically relevant
genes in PTC.
To answer both questions, we used the support vector
machines (SVMs) method with bootstrapping. This
approach relies on iterative construction of SVM
classiﬁers based on randomly selected sets of specimens
(bootstrap samples) and testing the classiﬁers on
remaining samples. We applied bootstrap to obtain both
gene (feature) ranking and outlier detection. The ranking
of the genes that are most important for classiﬁcation
quality was based on the frequency of their occurrence in
the classiﬁers of different size (bootstrap-based feature
ranking,BBFR).Therankingofthemisclassiﬁedsamples
allowed to detect outliers (bootstrap-based outlier detec-
tion, BBOD) and to obtain a reliable estimate of
classiﬁcation accuracy with appropriate conﬁdence
intervals (CI) for gene sets of different size.
Material and methods
Microarray data used in the study
Microarray datasets from three sources were included
in the analysis:
1. Dataset obtained in Gliwice, Poland; in total, 90
specimens analyzed with GeneChip HG-U133A
microarrays. The specimens were collected from
71 patients with PTC (9 males and 40 females;
mean age 36 years, range 6–71 years) and 22 with
other thyroid diseases, 6 with follicular adenoma,
13 with nodular or colloid goiter and 3 with
chronic thyroiditis (9 males and 13 females; mean
age 45 years, range 11–71 years). The thyroid
tissue specimens included 49 PTC tumors and 41
normal/benign thyroid tissue samples. The latter
samples were from patients with PTC (nZ17) or
other benign thyroid lesions (nZ24), among
them six follicular adenomas, four nodular
goiters, nine colloid goiters, and ﬁve cases of
thyroiditis, two of them taken from the contral-
ateral lobe from patients with PTC. Fifty
microarrays were included in our previously
published study and publicly available at
www.genomika.pl/thyroidcancer (Jarzab et al.
2005); 40 microarrays were from de novo studies.
All new samples were processed according to
description given in Jarzab et al. (2005).
2. Dataset obtained in Leipzig, Germany; 74 speci-
mens analyzed with GeneChip HG-U95Av2
microarrays. The specimens included 15 autono-
mously functioning thyroid nodules, 22 cold
thyroid nodules, and 37samplesoftheir respective
surrounding thyroid tissues. The analysis of these
datasets was published previously (Eszlinger et al.
2001, 2004) and the datasets are available athttp://
www.uni-leipzig.de/innere/_forschung/schwer-
punkte/etiology.html.
3. Dataset obtained in Columbus, OH, USA; 16
specimens analyzed with GeneChip HG-U95A
microarrays. The specimens were derived from
eight patients and included both PTC tumors and
their surrounding thyroid tissues. The dataset
(Huang et al. 2001) is publicly available at http://
thinker.med.ohio-state.edu.
In total, the three analyzed datasets comprised 57
PTCs, 61 benign thyroid lesions, and 62 apparently
normal thyroid tissues analyzed on 180 GeneChips of
two different generations. Half of them were U133A
and the rest U95A platforms.
Data pre-processing and generation of datasets
Each dataset was pre-processed by the MAS5
algorithm. To compare the expression data generated
using the U95A GeneChips (12 625 probe sets) with
those from the U133A GeneChips (22 283 probe sets),
we used the ‘Human Genome U95 to Human
Genome U133 Best Match Comparison Spreadsheet’
(www.affymetrix.com/support/technical/comparison_
spreadsheets.affx) which yielded an intersection of
9530 probe sets. The obtained data were log2
transformed.
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in gene selection
For selection of gene sets with diagnostic potential, we
applied here the recursive feature elimination (RFE)
algorithm (Guyon et al. 2002) which is computationally
less demanding than recursive feature replacement used
inourpreviousstudies(Jarzabetal.2005,Eszlingeretal.
2006). The introductory gene selection was performed
using neighborhood analysis (200 genes; Golub et al.
1999, Slonim et al. 2000), further selection of the 100
best genes set was carried out by RFE.
SVMs and classiﬁcation
The linear SVM (Boser et al. 1992, Vapnik 1995)w a s
usedfordevelopingtheclassiﬁcationrule.Asmentioned
earlier, the classiﬁer was independently trained for
different numbers of selected genes (from 1 to 100).
Bootstrap for estimation of classiﬁer accuracy
and its CI
In order to determine the accuracy of the developed
classiﬁer, we performed classical bootstrap procedure
in 500 resampling iterations (selection with equal
probability and return of samples; Efron 1979).
Iterations of all stages of the classiﬁer construction
(i.e. gene preselection, gene selection, and classiﬁer
learning) were performed in each bootstrap, as
suggested previously (Simon et al. 2003). The
accuracy of the classiﬁer was calculated using the
0.632 bootstrap estimator (Efron 1983). The distri-
bution of the misclassiﬁcation rate obtained during all
bootstrap runs was used to estimate the 95% CI. The
accuracy of the classiﬁer and the CI were calculated for
different numbers of selected genes (up to 100).
Bootstrap based feature ranking (BBFR) and
outlier detection (BBOD)
The primary purpose of the bootstrap used in this study
was to estimate the accuracy of the molecular classiﬁer
for different sizes of gene subsets with appropriate CIs.
However, the computational effort for the bootstrap
technique may also be exploited to derive some
additional information. We apply two methods that
use the information collected during bootstrapping:
BBFR and BBOD. They are similar to the methods of
statistical learning based on resampling, such as
bagging and boosting. In both techniques, an ensemble
of many base classiﬁers is created. Each base classiﬁer
is trained on different bootstrap subsamples. The ﬁnal
decision is based on decisions of all base classiﬁers.
The simplest approach is bagging (bootstrap aggregat-
ing) originally proposed by Breiman (1996).
In bagging, the subsamples are randomly drawn as in
classical bootstrapping where each observation is
picked with the same probability 1/m, where m is the
number of all observations. The ﬁnal decision is the
decision of most base classiﬁers. In boosting, different
observations may be picked with different probability
and the ﬁnal decision is weighted sum of decisions of
base classiﬁers. The well-known boosting algorithm is
AdaBoost (Freund & Schapire 1996).
In our approach, we do not create an ensemble
(committee) of many base classiﬁers but we use the
information collected during bootstrap-based vali-
dation step of the SVM classiﬁer.
Let the data contain m instances (observations). One
instance is a vector of Nmax features (gene expression
values) with a corresponding class label speciﬁed by an
expert. Let LB be the number of bootstrap iterations.
In each run, we select (with equal probability and
return of samples) m instances from the dataset
(bootstrap sample). Then, the bootstrap sample is
used for feature selection and classiﬁer learning.
Finally, the classiﬁer is tested on the test set containing
all instances not belonging to the bootstrap sample.
To ﬁnd the optimal size for the feature set, we select
N feature sets U1,U2,.,UN of sizes 1,2,.,N respect-
ively. In general, selected sets may not overlap, but in
most commonly used feature selection methods, based
on feature ranking or backward/forward searching,
feature subsets satisfy the relation
U13U23.3UN (1)
BBFR
Let rj(i) be a number of subsets Ui, iZ1,2,.,N where
the gene j belongs to. For gene selection methods
satisfying equation (1), we have
rjðiÞ ZNKðposition in the feature rankingÞC1: (2)
The BBFR score Rj of the feature j is deﬁned as a
sum of rj(i) over all bootstrap runs as follows:
Rj Z
X LB
iZ1
rjðiÞ (3)
The maximum possible value of the BBFR score is
LBN.
BBOD
Let qk be the number of bootstrap iterations where the
observation k is chosen as a test instance (not a member
Endocrine-Related Cancer (2007) 14 809–826
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bootstrap iterations where the instance j is correctly
classiﬁed at the test stage.
The BBOD score for k-th observation is
Qk Z
qk true
qk
(4)
The value of Qk belongs to the interval h0,1i and the
low value indicates outliers.
Comparison of different class prediction
methods
We used BRB ArrayTools (developed by Dr Richard
S i m o na n dA m yP e n gL a m )t oc o m p a r ed i f f e r e n tc l a s s
prediction algorithms (Compound Covariate Predictor,
Linear Diagonal Discriminant Analysis, Nearest Centroid,
1-Nearest Neighbor, 3-Nearest Neighbors and SVMs).
To compute misclassiﬁcation rate, 0.632 bootstrap cross-
validation method was used. All genes with univariate
misclassiﬁcationratebelow0.2wereusedforthisanalysis.
Results
Accuracy of malignant/benign classiﬁcation and
redundancy of PTC gene classiﬁers
The huge difference in gene expression between PTC and
benign/normal thyroid tissues implies that many multi-
gene classiﬁers with similar classiﬁcation ability may be
created. For preliminary assessment of accuracy of the
differentiation between PTC and benign lesions ornormal
thyroid, we randomly divided the 180-array dataset into
two subgroups, according to sample number: A (odd
numbers)andB(evennumbers).Eachsubgroupcontained
data from similar number of benign and malignant tumor
specimens analyzed with U133A or U95A GeneChips.
We used set A to obtain a 20-gene classiﬁer;this classiﬁer
was tested on set B and the procedure was repeated, using
set B as a training set and testing the classiﬁer on set A.
Using the classiﬁer obtained from set A, we were able to
correctly predict 86 out of 90 samples (95.6%) within set
B, while using the classiﬁer obtained from set B, we
accurately diagnosed 88 out of 90 samples in set A
(97.8%).Bothclassiﬁersdifferedpartlyfromourprevious
20-gene classiﬁer (37) obtained on a smaller dataset.
To avoid a bias in gene selection and accuracy
estimation, related to the arbitrary selection ofthe training
set,wecarriedouttheprocedureofaccuracyestimationby
bootstrapping, i.e. randomly selecting large numbers of
slightly different training sets and validating them on the
remaining samples. This procedure allows using suf-
ﬁcientlylargetrainingsetswhilesimultaneouslyobtaining
a reliable estimation of classiﬁcation accuracy. By
applying this method, we estimated the accuracy of
discrimination between benign and malignant samples to
be 98.6%, with a rather narrow CI (see Fig. 1). For small
gene sets, the accuracy was a bit lower (93.7% for one-
gene set, 96.9% for two-gene set, 97.9 for three-gene set,
andfrom98.3to98.6forlargersets,uptonZ100).Forthe
20-gene classiﬁer, the accuracy was 98.5% and the
estimated 95% CI was 95.9–100% for the classiﬁers
built from more than ﬁve genes.
We compared the results of classiﬁcation by the best
500 genes (Fig. 2) with the classiﬁcation by consecutive
500-gene sets (i.e. ﬁrst 500, 500–1000, 1000–1500, etc).
We noted that only the ﬁrst 500 genes allow accurately
classifying samples by single genes or small gene sets.
Genesranked500–1000achieved90%accuracyonlyfor
classiﬁers larger than 50 genes, while genes beyond the
ﬁrst1000hardlyachievethislimitofaccuracy.Whenwe
excluded all genes analyzed in Fig. 2 (8!500Z4000),
the accuracy obtained for small sets was only w60%,
close to random. However, the accuracy rose with gene
set size, and for classiﬁer sets larger than 700 genes it
achieved90%(datanotshown).Theseresultssupportthe
conclusion that the PTC transcriptome differs from the
normal one in thousands of genes; they also provide
evidence that optimizing a diagnostic gene set is a
necessarystepofanalysisinordertomakethissetuseful
for molecular PTC classiﬁcation.
Ranking of PTC genes for their classiﬁcation
ability
Toobtaintherankingofgenesbasedontheirusefulnessin
the diagnostic context, we performed subsequent repeti-
tive gene selection process by bootstrapping of the whole
dataset.Werankedallgenesaccordingtothefrequencyof
Figure 1 Accuracy of bootstrapping-estimated benign–malig-
nant classiﬁcation for different gene set sizes. The 95%
conﬁdence interval is marked by dashed lines.
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important for the majority of diagnostic datasets were
highly ranked, while less importance was given to
complementing transcripts, which exhibited higher
variability (Fig. 3). During the selection process, 365
transcripts occurred at least once within the obtained
classiﬁers and some of them were present in nearly all
classiﬁers. The maximum theoretical score to be obtained
by a gene was 5!10
4 and the gene with the best rank,
encoding metallophosphoesterase domain-containing
p r o t e i n2( MPPED2), had a score of 4.84!10
4,i . e .
96.7%ofthemaximumone.Theﬁrst20genesweregiven
scoresO3.74!10
4(O77% ofthemaximumscore), only
slightly lower than the top gene, and the ﬁrst 100
transcripts were characterized by scores O0.64!10
4,
which is O13.2% of the maximum score obtained. In
total, 43 transcripts representing 41 genes scored higher
than half of the value for the top gene (O2.42!10
4,
Fig. 3). Among them, there were both genes known for
their changed expression in PTC or described in previous
microarray studies, some used already as single markers,
as well as new genes, not considered previously for their
diagnostic potential (Table 1).
We analyzed fold-change differences between PTC
and benign thyroid samples for the 43 selected
transcripts to evaluate the potential inﬂuence of inter-
platform differences on the obtained gene selection.
Twenty of them showed more than fourfold increase
(log ratio O2) and four transcripts were increased
more than twice, whereas the remaining 19 transcripts
were decreased. Generally, the consistency between
fold-changes observed in subsets from U95 and U133
arrays was good, although for some genes (e.g. the
well-known thyroid cancer markers ﬁbronectin 1
(FN1) and MET or novel genes cadherin 16 (CDH16)
or gap junction protein b-3 (GJB3)) there were inter-
platform differences between the log ratios. However,
40 out of 43 selected genes exhibited more than
twofold change in both the U133 and the U95 subsets.
For all 43 genes, the PTC–benign difference was larger
than the difference between fold-changes obtained with
different GeneChip generation subsets. This conﬁrms
that the selection performed was robust to inter-array
differences.
Misclassiﬁed thyroid samples
The algorithm with bootstrapping allows ranking the
samples according to the frequency of their misclassiﬁ-
cation (Table 2). BBOF showed very frequent
misclassiﬁcations for two samples. One of them was
not properly classiﬁed by any gene set selected, and
this was sample no. 154 from the U133 dataset no. 1, a
small (10 mm in diameter) familial PTC found within a
larger follicular adenoma. It was observed in an
18-year-old woman. A year later her mother, 43
years old, was diagnosed with 0.7 cm PTC (follicular
Figure 2 Accuracy of classiﬁcation obtained by successive
gene set reduction. The accuracy of the best 500 genes was
evaluated in one iteration using the bootstrap technique, then
the selected 500-gene set was removed from the whole
dataset, and the next 500 genes were selected in the following
iteration. This procedure was repeated seven times, thus 3500
genes were excluded (line no. 8). To speed up the procedure,
only neighbourhood analysis (NA) was used for gene selection.
Figure 3 Result of bootstrap-based feature ranking (BBFR). Each
dotrepresentsonegene,dashedlinesdeﬁnethesubsetof43genes
with BBFR score larger than half of the maximum one (black dots).
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www.endocrinology-journals.org 813Table 1 Ranking of papillary thyroid cancer (PTC) genes as assessed by bootstrap-based feature ranking (BBFR) approach. For each transcript selected, rank and score obtained by
the BBFR method are given, together with basic univariate statistics (log2 mean and log2 ratio)
Gene
symbol Gene name
Affy_ID
(U133) Rank Score
PTC
mean
log2
Benign
mean
log2
Log
ratio
Log ratio
U133
Log ratio
U95
References of microarray or other
high throughput studies
a
Referred to in
single studies of
thyroid cancer
Other data
relevant for
functional role in
thyroid cancer Gene function
b
MPPED2 Metallophosphoestera-
se domain-
containing protein 2
205413_at 1 48 449 4.66 7.82 K3.16 K3.46 K3.26 Aldred et al. (2003, 2004), Mazzanti et al.
(2004) and Grifﬁth et al. (2006)
Fetal brain protein of unknown function
H/HBA2 Hemoglobin, a-1/hemo-
globin, a-2
209458_x_at 2 45 521 9.79 12.04 K2.25 K2.28 K1.87 Grifﬁth et al. (2006) Onda et al. (2005) Oxygen transport
MET Met proto-oncogene
(hepatocyte growth
factor receptor)
213807_x_at 3 45 363 8.15 5.22 2.93 1.73 2.60 Barden et al. (2003), Wasenius et al.
(2003), Finley et al. (2004a,b), Prasad
et al. (2004), Zou et al. (2004) and
Giordano et al. (2005)
cBelﬁore et al.
(1997) and
cIppolito et al.
(2001)
Ramirez et al.
(2000), Ruco
et al. (2001) and
Scarpino et al.
(2004)
Membrane tyrosine kinase receptor
enhances cell motility, invasiveness,
and chemokine production (Ruco
et al. (2001))
FN1 Fibronectin 1 210495_x_at 4 44 017 12.24 8.72 3.52 2.75 3.91 Chen et al. (2001), Barden et al. (2003),
Wasenius et al. (2003) Finley et al.
(2004a,b), Prasad et al. (2004),Giordano
et al. (2005), Hamada et al. (2005) and
Grifﬁth et al. (2006)
Takano et al.
(1998), 1999
and
cPrasad
et al. (2005)
Ghinea et al. (2002)
and Liu et al. (2005)
Extracellular matrix glycoprotein partici-
pates in cell adhesion, regulates
proliferation and survival of thyroid
cells via integrin receptors (Illario et
al. (2003))
GALE UDP-galactose-4-epi-
merase
202528_at 5 43 974 7.12 3.70 3.42 2.41 3.50 Converts glucose to galactose and
N-acetylglucosamine to its UDP-
derivatives
QPCT Glutaminyl-peptide
cyclotransferase
(glutaminyl cyclase)
205174_s_at 6 43 317 7.60 4.99 2.61 3.14 2.56 Barden et al. (2003), Chevillard et al.
(2004), Finley et al. (2004a,b) and
Grifﬁth et al. (2006)
Converts glutaminyl peptides to cyclic
pyroglutamyl ones
NELL2 NEL-like 2 (chicken) 203413_at 7 42 953 9.68 7.56 2.12 2.02 2.53 Barden et al. (2003) and Finley et al.
(2004a,b)
Brain protein with six EGF-like repeats
PGCP Plasma glutamate
carboxypeptidase
203501_at 8 42 153 7.70 9.23 K1.53 K1.05 K1.33 Aldred et al. (2003, 2004), Barden et al.
(2003), Finley et al. (2004a,b), Weber
et al. (2005) and Sarquis et al. (2006)
Breakdown of secreted peptides, hom-
ologous to prostate membrane-
speciﬁc antigen (Gingras et al.
(1999))
DPP4 Dipeptidylpeptidase 4
(CD26, adenosine
deaminase com-
plexing protein 2)
203717_at 9 42 115 7.87 3.77 4.11 3.21 3.81 Huang et al. (2001), Takano et al. (2002,
2004), Prasad et al. (2004) and Grifﬁth
et al. (2006)
Kehlen et al. (2003),
cKholova et al.
(2003a,b) and Ozog
et al. (2006)
Aratake et al.
(2006) and
Schagdarsurengin
et al. (2006)
Membrane enzyme, participates in
breakdown of secreted peptides
ADORA1 Adenosine A1 receptor 205481_at 10 41 699 7.16 4.85 2.30 2.00 2.81 Aldred et al. (2003, 2004) and Prasad
et al. (2004)
Lelievre et al.
(1998), Woodhouse
et al. (1998) and
Schnurr et al. (2004)
Membrane receptor, stimulates motility
and modulates proliferation
HMGA2 High-mobility group
AT-hook 2
208025_s_at 11 40 713 7.90 4.66 3.24 3.58 2.62 Baris et al. (2004, 2005) and Jacques
et al. (2005)
Fedele et al. (2001),
Berlingieri et al.
(2002) and Musholt
et al. (2006)
Architectural transcription factor (Noro
et al. (2003))
RYR1 Ryanodine receptor 1
(skeletal)
205485_at 12 40 473 6.96 4.70 2.27 2.53 1.92 Barden et al. (2003) and Finley et al.
(2004a,b)
Present mainly in
excitable cells
Calcium release channel of the sarco-
plasmic reticulum
CDH16 Cadherin 16, KSP-cad-
herin
206517_at 13 39 770 3.47 8.07 K4.60 K4.68 K1.43 Thoughttobekidney
speciﬁc (Thomson
et al. (1995))
Calcium-dependent, membrane-associ-
ated glycoprotein, participates in cell
adhesion
GJB3 Gap junction protein b-
3, 31 kDa (connexin
31)
205490_x_at 14 39 526 6.49 4.04 2.44 2.71 0.62 Does not normally
appear in thyroid, in
adult mouse
becomes restricted
to epidermis, testis
and placenta (Tonoli
et al. (2000), Plum
et al. (2002) and
Green et al. (2005)
Forms incompatible hemichannels with
thyroidal connexin 43 (Dahl et al.
(1996))
EMID1 EMI domain containing
1
213779_at 15 39 505 6.44 8.12 K1.68 K1.09 K0.76 Barden et al. (2003), Cerutti et al. (2004)
and Finley et al. (2004a,b)
Extracellular matrix protein, able to
promote cell movements (Spessotto
et al. (2003))
NRIP1 Nuclear receptor-inter-
acting protein 1
202599_s_at 16 39 358 8.31 6.33 1.98 1.36 2.06 Barden et al. (2003) and Finley et al.
(2004a,b)
Interacts with nuclear receptors
K
F
u
j
a
r
e
w
i
c
z
e
t
a
l
.
:
M
u
l
t
i
-
g
e
n
e
d
i
f
f
e
r
e
n
t
i
a
t
i
o
n
o
f
P
T
C
w
w
w
.
e
n
d
o
c
r
i
n
o
l
o
g
y
-
j
o
u
r
n
a
l
s
.
o
r
g
8
1
4T
a
b
l
e
1
(
c
o
n
t
i
n
u
e
d
)
G
e
n
e
s
y
m
b
o
l
G
e
n
e
n
a
m
e
A
f
f
y
_
I
D
(
U
1
3
3
)
R
a
n
k
S
c
o
r
e
P
T
C
m
e
a
n
l
o
g
2
B
e
n
i
g
n
m
e
a
n
l
o
g
2
L
o
g
r
a
t
i
o
L
o
g
r
a
t
i
o
U
1
3
3
L
o
g
r
a
t
i
o
U
9
5
R
e
f
e
r
e
n
c
e
s
o
f
m
i
c
r
o
a
r
r
a
y
o
r
o
t
h
e
r
h
i
g
h
t
h
r
o
u
g
h
p
u
t
s
t
u
d
i
e
s
a
R
e
f
e
r
r
e
d
t
o
i
n
s
i
n
g
l
e
s
t
u
d
i
e
s
o
f
t
h
y
r
o
i
d
c
a
n
c
e
r
O
t
h
e
r
d
a
t
a
r
e
l
e
v
a
n
t
f
o
r
f
u
n
c
t
i
o
n
a
l
r
o
l
e
i
n
t
h
y
r
o
i
d
c
a
n
c
e
r
G
e
n
e
f
u
n
c
t
i
o
n
b
M
E
T
M
e
t
p
r
o
t
o
-
o
n
c
o
g
e
n
e
(
h
e
p
a
t
o
c
y
t
e
g
r
o
w
t
h
f
a
c
t
o
r
r
e
c
e
p
t
o
r
)
2
1
1
5
9
9
_
x
_
a
t
1
7
3
9
3
4
8
8
.
4
4
5
.
6
8
2
.
7
6
1
.
5
3
2
.
5
4
B
a
r
d
e
n
e
t
a
l
.
(
2
0
0
3
)
,
W
a
s
e
n
i
u
s
e
t
a
l
.
(
2
0
0
3
)
,
F
i
n
l
e
y
e
t
a
l
.
(
2
0
0
4
a
,
b
)
,
P
r
a
s
a
d
e
t
a
l
.
(
2
0
0
4
)
,
Z
o
u
e
t
a
l
.
(
2
0
0
4
)
a
n
d
G
i
o
r
d
a
n
o
e
t
a
l
.
(
2
0
0
5
)
S
e
e
t
h
e
i
n
f
o
r
m
a
t
i
o
n
g
i
v
e
n
a
b
o
v
e
f
o
r
a
n
o
t
h
e
r
p
r
o
b
e
s
e
t
o
f
t
h
e
s
a
m
e
g
e
n
e
D
T
X
4
D
e
l
t
e
x
4
h
o
m
o
l
o
g
(
D
r
o
-
s
o
p
h
i
l
a
)
2
1
2
6
1
1
_
a
t
1
8
3
9
2
9
8
1
0
.
2
4
8
.
2
4
2
.
0
0
2
.
0
7
1
.
4
5
P
r
a
s
a
d
e
t
a
l
.
(
2
0
0
4
)
P
a
r
t
i
c
i
p
a
t
e
s
i
n
p
r
o
t
e
i
n
u
b
i
q
u
i
n
a
t
i
o
n
R
A
B
2
7
A
R
A
B
2
7
A
,
m
e
m
b
e
r
R
A
S
o
n
c
o
g
e
n
e
f
a
m
i
l
y
2
1
0
9
5
1
_
x
_
a
t
1
9
3
8
9
1
3
8
.
6
2
5
.
6
2
3
.
0
0
1
.
6
0
1
.
2
4
B
a
r
d
e
n
e
t
a
l
.
(
2
0
0
3
)
,
F
i
n
l
e
y
e
t
a
l
.
(
2
0
0
4
a
,
b
)
,
W
e
b
e
r
e
t
a
l
.
(
2
0
0
5
)
,
M
u
s
h
o
l
t
e
t
a
l
.
(
2
0
0
6
)
a
n
d
S
a
r
q
u
i
s
e
t
a
l
.
(
2
0
0
6
)
P
r
e
n
y
l
a
t
e
d
m
e
m
b
r
a
n
e
b
o
u
n
d
p
r
o
t
e
i
n
w
i
t
h
G
T
P
-
a
s
e
f
u
n
c
t
i
o
n
–
C
D
N
A
c
l
o
n
e
I
M
A
G
E
:
4
1
5
2
9
8
3
2
1
4
8
0
3
_
a
t
2
0
3
7
3
9
7
7
.
3
0
5
.
3
9
1
.
9
0
1
.
9
4
1
.
2
3
N
o
t
i
d
e
n
t
i
ﬁ
e
d
B
C
L
2
B
-
c
e
l
l
C
L
L
/
l
y
m
p
h
o
m
a
2
2
0
3
6
8
4
_
s
_
a
t
2
1
3
6
4
8
3
2
.
9
2
5
.
8
8
K
2
.
9
5
K
2
.
7
4
K
1
.
3
9
H
o
o
s
e
t
a
l
.
(
2
0
0
2
)
,
B
a
r
i
s
e
t
a
l
.
(
2
0
0
4
,
2
0
0
5
)
,
P
r
a
s
a
d
e
t
a
l
.
(
2
0
0
4
)
,
W
r
e
e
s
m
a
n
n
e
t
a
l
.
(
2
0
0
4
)
,
G
i
o
r
d
a
n
o
e
t
a
l
.
(
2
0
0
5
)
a
n
d
J
a
c
q
u
e
s
e
t
a
l
.
(
2
0
0
5
)
M
i
t
s
e
l
o
u
e
t
a
l
.
(
2
0
0
4
)
,
c
A
k
s
o
y
e
t
a
l
.
(
2
0
0
5
)
a
n
d
c
L
e
t
s
a
s
e
t
a
l
.
(
2
0
0
5
)
S
t
a
s
s
i
e
t
a
l
.
(
2
0
0
3
)
a
n
d
B
a
s
o
l
o
e
t
a
l
.
(
1
9
9
9
)
A
n
t
i
-
a
p
o
p
t
o
t
i
c
p
r
o
t
e
i
n
T
A
C
S
T
-
D
2
T
u
m
o
r
-
a
s
s
o
c
i
a
t
e
d
c
a
l
c
i
u
m
s
i
g
n
a
l
t
r
a
n
s
d
u
c
e
r
2
2
0
2
2
8
6
_
s
_
a
t
2
2
3
6
1
7
0
1
0
.
4
2
6
.
2
9
4
.
1
3
4
.
0
2
4
.
0
2
G
i
o
r
d
a
n
o
e
t
a
l
.
(
2
0
0
5
)
M
a
y
s
e
r
v
e
a
s
c
e
l
l
s
u
r
f
a
c
e
r
e
c
e
p
t
o
r
D
I
O
1
D
e
i
o
d
i
n
a
s
e
,
i
o
d
o
t
h
y
r
o
-
n
i
n
e
,
t
y
p
e
I
2
0
6
4
5
7
_
s
_
a
t
2
3
3
5
9
7
1
6
.
1
9
9
.
9
4
K
3
.
7
5
K
3
.
7
9
K
4
.
3
3
E
s
z
l
i
n
g
e
r
e
t
a
l
.
(
2
0
0
1
,
2
0
0
4
)
,
H
u
a
n
g
e
t
a
l
.
(
2
0
0
1
)
,
B
a
r
d
e
n
e
t
a
l
.
(
2
0
0
3
)
,
F
i
n
l
e
y
e
t
a
l
.
(
2
0
0
4
a
,
b
)
,
P
r
a
s
a
d
e
t
a
l
.
(
2
0
0
4
)
,
W
r
e
e
s
m
a
n
n
e
t
a
l
.
(
2
0
0
4
)
,
G
i
o
r
d
a
n
o
e
t
a
l
.
(
2
0
0
5
)
a
n
d
G
r
i
f
ﬁ
t
h
e
t
a
l
.
(
2
0
0
6
)
c
D
e
M
i
c
c
o
e
t
a
l
.
(
1
9
9
9
)
,
c
C
z
a
r
n
o
c
k
a
e
t
a
l
.
(
2
0
0
1
)
,
c
L
e
F
o
u
r
n
e
t
a
l
.
(
2
0
0
4
)
,
c
A
m
b
r
o
z
i
a
k
e
t
a
l
.
(
2
0
0
5
)
a
n
d
c
A
r
n
a
l
d
i
e
t
a
l
.
(
2
0
0
5
)
K
o
h
r
l
e
(
1
9
9
9
)
5
0
D
e
i
o
d
i
n
a
t
i
o
n
o
f
t
h
y
r
o
x
i
n
e
I
T
P
R
1
I
n
o
s
i
t
o
l
1
,
4
,
5
-
t
r
i
p
h
o
-
s
p
h
a
t
e
r
e
c
e
p
t
o
r
,
t
y
p
e
1
2
0
3
7
1
0
_
a
t
2
4
3
4
8
0
4
6
.
7
5
8
.
8
4
K
2
.
0
9
K
2
.
0
6
K
1
.
8
3
B
a
r
d
e
n
e
t
a
l
.
(
2
0
0
3
)
,
F
i
n
l
e
y
e
t
a
l
.
(
2
0
0
4
a
,
b
)
,
P
r
a
s
a
d
e
t
a
l
.
(
2
0
0
4
)
,
W
r
e
e
s
m
a
n
n
e
t
a
l
.
(
2
0
0
4
)
a
n
d
H
a
m
a
d
a
e
t
a
l
.
(
2
0
0
5
)
S
i
g
n
a
l
t
r
a
n
s
d
u
c
e
r
c
o
u
p
l
e
d
w
i
t
h
c
a
l
c
i
u
m
c
h
a
n
n
e
l
s
,
p
a
r
t
i
c
i
p
a
t
e
s
i
n
a
p
o
p
t
o
s
i
s
(
S
e
d
l
a
k
&
S
n
y
d
e
r
(
2
0
0
6
)
)
H
B
B
H
e
m
o
g
l
o
b
i
n
b
2
0
9
1
1
6
_
x
_
a
t
2
5
3
4
5
9
1
9
.
6
2
1
2
.
1
3
K
2
.
5
1
K
2
.
4
8
K
1
.
2
4
A
l
d
r
e
d
e
t
a
l
.
(
2
0
0
3
,
2
0
0
4
)
a
n
d
O
n
d
a
e
t
a
l
.
(
2
0
0
5
)
S
e
e
a
b
o
v
e
t
h
e
H
B
A
g
e
n
e
S
N
E
D
1
S
u
s
h
i
,
n
i
d
o
g
e
n
,
a
n
d
E
G
F
-
l
i
k
e
d
o
m
a
i
n
s
1
2
1
3
4
9
3
_
a
t
2
6
3
3
6
2
5
2
.
8
7
5
.
8
8
K
3
.
0
1
K
2
.
1
4
K
2
.
0
6
P
a
r
t
i
c
i
p
a
t
e
s
i
n
c
e
l
l
–
m
a
t
r
i
x
a
d
h
e
s
i
o
n
,
c
o
n
t
a
i
n
s
s
u
s
h
i
,
n
i
d
o
g
e
n
-
a
n
d
c
a
l
c
i
u
m
-
b
i
n
d
i
n
g
d
o
m
a
i
n
s
A
H
R
A
r
y
l
h
y
d
r
o
c
a
r
b
o
n
r
e
c
e
p
t
o
r
2
0
2
8
2
0
_
a
t
2
7
3
3
0
0
3
7
.
5
2
6
.
0
2
1
.
5
0
1
.
2
0
1
.
5
9
B
a
r
d
e
n
e
t
a
l
.
(
2
0
0
3
)
,
W
a
s
e
n
i
u
s
e
t
a
l
.
(
2
0
0
3
)
a
n
d
F
i
n
l
e
y
e
t
a
l
.
(
2
0
0
4
a
,
b
)
A
l
i
g
a
n
d
-
a
c
t
i
v
a
t
e
d
t
r
a
n
s
c
r
i
p
t
i
o
n
f
a
c
t
o
r
a
b
l
e
t
o
f
o
r
m
c
o
m
p
l
e
x
e
s
w
i
t
h
o
t
h
e
r
n
u
c
l
e
a
r
r
e
c
e
p
t
o
r
s
(
W
i
d
e
r
a
k
e
t
a
l
.
(
2
0
0
5
)
H
G
D
H
o
m
o
g
e
n
t
i
s
a
t
e
1
,
2
-
d
i
o
x
y
g
e
n
a
s
e
(
h
o
m
o
-
g
e
n
t
i
s
a
t
e
o
x
i
d
a
s
e
)
2
0
5
2
2
1
_
a
t
2
8
3
2
8
1
6
4
.
5
7
7
.
8
3
K
3
.
2
6
K
3
.
1
7
K
3
.
9
2
H
u
a
n
g
e
t
a
l
.
(
2
0
0
1
)
,
A
l
d
r
e
d
e
t
a
l
.
(
2
0
0
3
)
,
B
a
r
d
e
n
e
t
a
l
.
(
2
0
0
3
)
,
A
l
d
r
e
d
e
t
a
l
.
(
2
0
0
4
)
,
F
i
n
l
e
y
e
t
a
l
.
(
2
0
0
4
a
,
b
)
,
P
r
a
s
a
d
e
t
a
l
.
(
2
0
0
4
)
a
n
d
G
i
o
r
d
a
n
o
e
t
a
l
.
(
2
0
0
5
)
F
e
(
I
I
)
-
d
e
p
e
n
d
e
n
t
e
n
z
y
m
e
r
e
s
p
o
n
s
i
b
l
e
f
o
r
a
r
o
m
a
t
i
c
r
i
n
g
c
l
e
a
v
a
g
e
R
X
R
G
R
e
t
i
n
o
i
d
X
r
e
c
e
p
t
o
r
,
g
2
0
5
9
5
4
_
a
t
2
9
3
2
4
4
4
7
.
3
5
4
.
6
9
2
.
6
6
2
.
8
0
2
.
6
2
H
a
u
g
e
n
e
t
a
l
.
(
2
0
0
4
)
K
l
o
p
p
e
r
e
t
a
l
.
(
2
0
0
4
)
,
S
c
h
m
u
t
z
l
e
r
e
t
a
l
.
(
2
0
0
4
)
a
n
d
F
r
o
h
l
i
c
h
e
t
a
l
.
(
2
0
0
5
)
H
e
t
e
r
o
d
i
m
e
r
p
a
r
t
n
e
r
o
f
s
e
v
e
r
a
l
n
u
c
l
e
a
r
r
e
c
e
p
t
o
r
s
C
A
4
C
a
r
b
o
n
i
c
a
n
h
y
d
r
a
s
e
I
V
2
0
6
2
0
9
_
s
_
a
t
3
0
3
1
3
3
2
6
.
3
3
8
.
5
1
K
2
.
1
8
K
2
.
6
2
K
1
.
4
1
B
a
r
d
e
n
e
t
a
l
.
(
2
0
0
3
)
,
F
i
n
l
e
y
e
t
a
l
.
(
2
0
0
4
a
,
b
)
,
W
e
b
e
r
e
t
a
l
.
(
2
0
0
5
)
a
n
d
S
a
r
q
u
i
s
e
t
a
l
.
(
2
0
0
6
)
A
n
a
n
c
i
e
n
t
i
s
o
z
y
m
e
S
D
C
4
S
y
n
d
e
c
a
n
4
(
a
m
p
h
i
-
g
l
y
c
a
n
,
r
y
u
d
o
c
a
n
)
2
0
2
0
7
1
_
a
t
3
1
2
8
0
3
6
1
0
.
7
6
8
.
3
1
2
.
4
5
1
.
8
6
2
.
4
1
B
a
r
d
e
n
e
t
a
l
.
(
2
0
0
3
)
,
C
h
e
v
i
l
l
a
r
d
e
t
a
l
.
(
2
0
0
4
)
,
F
i
n
l
e
y
e
t
a
l
.
(
2
0
0
4
a
,
b
)
,
P
r
a
s
a
d
e
t
a
l
.
(
2
0
0
4
)
a
n
d
G
r
i
f
ﬁ
t
h
e
t
a
l
.
(
2
0
0
6
)
T
r
a
n
s
m
e
m
b
r
a
n
e
h
e
p
a
r
a
n
s
u
l
f
a
t
e
p
r
o
-
t
e
o
g
l
y
c
a
n
i
n
v
o
l
v
e
d
i
n
t
h
e
o
r
g
a
n
i
z
-
a
t
i
o
n
o
f
t
h
e
a
c
t
i
n
c
y
t
o
s
k
e
l
e
t
o
n
a
n
d
i
n
c
e
l
l
–
m
a
t
r
i
x
i
n
t
e
r
a
c
t
i
o
n
s
,
b
i
n
d
s
ﬁ
b
r
o
-
n
e
c
t
i
n
,
b
e
h
a
v
e
s
a
s
C
X
C
L
1
2
r
e
c
e
p
t
o
r
(
L
i
n
e
t
a
l
.
(
2
0
0
5
)
)
(
c
o
n
t
i
n
u
e
d
)
Endocrine-Related Cancer (2007) 14 809–826
www.endocrinology-journals.org 815Table 1 (continued)
Gene
symbol Gene name
Affy_ID
(U133) Rank Score
PTC
mean
log2
Benign
mean
log2
Log
ratio
Log ratio
U133
Log ratio
U95
References of microarray or other
high throughput studies
a
Referred to in
single studies of
thyroid cancer
Other data
relevant for
functional role in
thyroid cancer Gene function
b
ENTPD1 Ectonucleoside tripho-
sphate diphospho-
hydrolase 1
209473_at 32 27 859 8.71 6.75 1.97 1.49 1.48 Weber et al. (2005) and Sarquis et al.
(2006)
Membrane bound enzyme converts
adenine nucleotides to adenosine,
interacts with caveolin 1 and 2 (Kittel
et al. (2004))
TPO Thyroid peroxidase 210342_s_at 33 27 658 7.29 12.24 K4.95 K4.93 K3.75 Barden et al. (2003), Cerutti et al.
(2004), Finley et al. (2004a,b) and
Grifﬁth et al. (2006)
Arturi et al. (1997),
Lazar et al. (1999)
and
Furuya et al. (2004) Thyroid-speciﬁc enzyme crucial for
organiﬁcation of iodine and synthesis
of thyroid hormones
KRT19 Keratin 19 201650_at 34 27 398 8.92 5.71 3.22 3.55 3.07 Barden et al. (2003), Chevillard et al.
(2004), Finley et al. (2004a,b), Prasad
et al. (2004) and Grifﬁth et al. (2006)
Schelfhout et al.
(1989)
The smallest known keratin expressed
in some types of cancer
ID3 Inhibitor of DNA binding
3, dominant
negative helix-loop-
helix protein
207826_s_at 35 26 271 9.17 11.25 K2.08 K1.26 K1.29 Downstream target of pituitary tumor
transforming gene (PTTG)
RUNX1 Runt-related transcrip-
tion factor 1 (acute
myeloid leukemia 1;
aml1 oncogene)
209360_s_at 36 26 202 7.37 4.80 2.58 3.50 2.01 Kim et al. (2007) Transcription factor may promote E-
cadherin expression (Liu et al.
(2005))
LMOD1 Leiomodin 1 (smooth
muscle)
203766_s_at 37 26 044 5.60 7.80 K2.20 K2.77 K0.95 Present both in
thyroid cells and
eye muscle
(Kromminga
et al. (1998))
64 kDa antigen, considered for its role in
thyroid autoimmunity
RAB27A RAB27A, member RAS
oncogene family
209514_s_at 38 25 684 8.57 6.29 2.28 1.43 1.53 Barden et al. (2003), Finley et al.
(2004a,b), Weber et al. (2005) and
Sarquis et al. (2006)
See above information on the alterna-
tive probeset identifying the same
gene
FBXO9 F-box protein 9 212987_at 39 25 331 8.47 9.29 K0.83 K0.50 K0.57 Members of this gene family in
complexes may act as protein–
ubiquitin ligases
TRIM58 Tripartite motif-
containing 58
215047_at 40 25 304 3.91 6.99 K3.08 K2.27 K1.74 Not identiﬁed
– – 210524_x_at 41 25 302 9.73 12.70 K2.97 K2.95 K2.12 Not identiﬁed
MT1G Metallothionein 1G 204745_x_at 42 24 688 9.94 12.39 K2.45 K1.97 K4.00 Baris et al. (2004, 2005), Prasad et al.
(2004), Jacques et al. (2005) and Grifﬁth
et al. (2006)
Cherian et al.
(2003)
Low molecular weight, cysteine-rich,
zinc-donating protein. Associated
with protection against DNA
damage, stress, and apoptosis
(Theocharis et al. (2004))
ICAM1 Intercellular adhesion
molecule 1 (CD54),
human rhinovirus
receptor
202638_s_at 43 24 534 8.18 5.61 2.57 1.70 2.40 Kawai et al. (1998) Epithelial adhesion molecule plays a key
role in lymphocyte inﬁltration into the
thyroid
aThe original papers (Eszlingeretal.2001,2004,Huangetal.2001,Jarzabetal.2005)containingdatasetsincludedinthepresentstudywerenotcitedhere.RXRGwaslistedinourprevious
microarray-based analysis (Jarzab et al. 2005), together with FN1, MET, KRT19, DPP4, HBB, QPCT, GJB3, and DTX4, also occurring in this table.
bOMIM-based information if not otherwise speciﬁed.
cDenotes immunohistochemistry studies.
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6variant). The other one, properly classiﬁed only in 8%
of runs, was a benign follicular adenoma (diagnosed as
atypical) from the same dataset (sample no. 97) which
was derived from a 15-year-old boy of another family
with familial PTC. In this family, there were two PTC
cases (mother of the patient, diagnosed with
pT2BNxM0 PTC and her aunt who died of a
dissemination of PTC) and one follicular thyroid
cancer case (pT2bNxM0, 11 years old, sister of the
patient). These were the only two cases with a positive
family history of thyroid cancer among 49 Polish
patients included in the study. Two further samples
were properly classiﬁed in 65–68% of runs (one from
dataset no. 1 and one from dataset no. 3), again one
benign adenoma and one PTC, respectively. For the
ﬁfth sample, the accuracy was much higher and it was
properly classiﬁed in 88% of the runs. Thus, only 5 out
of 180 samples (2.8%) were misclassiﬁed in more than
10% of the runs, while a total of 14 samples (7.8%)
were misclassiﬁed in more than 1% of the runs.
Seventy samples were classiﬁed with an excellent
accuracy between 99 and 100%, and for further 64
cases no misclassiﬁcation occurred during the boot-
strapping process.
Comparison of classiﬁcation accuracy by
different class prediction methods
To evaluate our method, we compared the accuracy of
prediction by different class prediction methods
implemented in BRB-Array software. We based the
class prediction on all genes that showed the univariate
misclassiﬁcation rate lower than 20%. We found out
that the classiﬁcation accuracy ranged from 89%
(compound covariate predictor method) to 99%
Table 2 Ranking of thyroid samples by tumor–normal misclassiﬁcation frequency, assessed by bootstrap-based outlier detection
(BBOD) approach. The BBOD rank and score Qk, as deﬁned in Material and methods, is given
Sample number Status Array Set Rank Score (%)
154 PTC U133 B 1 0.04
97 Benign U133 A 2 7.23
148 PTC U133 B 3 65.34
95 Benign U133 A 4 68.25
88 PTC U95v1 B 5 88.28
166 PTC U133 B 6 90.02
84 PTC U95v1 B 7 93.11
161 PTC U133 A 8 95.96
94 Benign U133 B 9 97.26
116 Normal U133 B 10 97.30
120 PTC U133 A 11 97.98
77 Normal U95v1 B 12 98.30
100 Benign U133 B 13 98.70
139 PTC U133 A 14 98.91
90 PTC U95v1 B 15 99.09
42 CTN U95v2 B 16 99.22
3 AFTN U95v2 A 17 99.28
37 CTN U95v2 A 18 99.36
147 PTC U133 A 19 99.38
40 CTN U95v2 B 20 99.41
64 samples (28 PTCs, 36 benign/normal) 21–84 99.46–99.98
96 samples (19 PTCs, 77 benign/normal) 85–180 100
Table 3 Comparison of results obtained by different class prediction methods
Method Accuracy (%) Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%)
Compound covariate predictor 89 85 88 77 93
Nearest centroid 90 86 89 79 93
Linear diagonal discriminant analysis 92 87 92 83 94
One-nearest neighbor 98 94 99 98 97
Three-nearest neighbors 98 93 100 99 97
Support vector machines 99 95 99 98 98
PPV, positive predictive value; NPV, negative predictive value.
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based methods to analyze these data (Table 3).
Discussion
Transcripts important for discriminating PTC
from benign and normal thyroid samples
In the study, we performed an advanced optimization
of putative PTC markers using a large group of benign
thyroid lesions and normal thyroid tissues and
proposed a list of 43 transcripts, selected by their
most frequent appearance in the classiﬁers.
An additional proof of their efﬁcacy was obtained by
hierarchical clustering (all samples clustered correctly,
data shown in the web appendix to this article,
www.genomika.pl/thyroidcancer). Forty-one of them
(95.3%) could be attributed to 39 known genes, 32
well-deﬁned ones, and 7 of unknown or not well-
deﬁned function. There were 12 genes which had never
before been related to the thyroid gland nor mentioned
in genomic studies of thyroid cancer, while 29 genes
(74%) were identiﬁed in previous thyroid microarray
studies. However, only ten of them were discussed in
the original papers for their putative role in thyroid
carcinoma. Within the list of the well-known genes
which received high scores by BBFR, one should
mention gene encoding FN1, met proto-oncogene
(MET; both scored 4.4!104), dipeptidylpeptidase 4
(DPP4), adenosine A1 receptor (ADORA1), keratin
19, and B-cell CLL (BCL2) genes (Huang et al. 2001,
Wasenius et al. 2003, Baris et al. 2004, Chevillard
et al. 2004, Finley et al. 2004a, Wreesmann et al. 2004,
Giordano et al. 2005), all up-regulated with the
exception of BCL2. Their inclusion in our classiﬁer
positively validates the applied criteria. All these genes
except ADORA1 were previously found by single gene
studies (see Table 1) and later conﬁrmed by microarray
approaches. Moreover, in the recent meta-analysis of
thyroid cancer gene expression proﬁle, MET and FN1
were included into top 12 candidates for consistent
gene expression markers (Grifﬁth et al. 2006).
Similarly, thyroid-speciﬁc (down-regulated) genes,
deiodinase, iodothyronine, type I and thyroid per-
oxidase, were widely recognized previously for their
diagnostic signiﬁcance both in microarray-based
(Eszlinger et al. 2001, Huang et al. 2001, Baris et al.
2004, Cerutti et al. 2004, Finley et al. 2004a,
Wreesmann et al. 2004) and single gene studies (Arturi
et al. 1997, Lazar et al. 1999, De Micco et al. 1999,
Czarnocka et al. 2001, Le Fourn et al. 2004,
Ambroziak et al. 2005, Arnaldi et al. 2005). Never-
theless, neither our approach nor the meta-analysis
mentioned earlier indicated other thyroid-speciﬁc
genes, conﬁrming the lesser diagnostic potency of
sodium iodide symporter, thyroglobulin, thyrotrophin
receptor, or thyroid-speciﬁc transcription factors,
shown to be down-regulated in previous single gene
studies (Arturi et al. 1997, Lazar et al. 1999, Shimura
et al. 2001, Scouten et al. 2004, Ambroziak et al. 2005,
Wagner et al. 2005).
Thetopgeneidentiﬁedbyoureffort,MPPED2,which
is lost in PTC, was not previously considered for its role
inPTC,althoughitwaspreviouslylistedbyAldredetal.
(2004, in the context of FTC) and by Mazzanti et al.
(2004). It is an ancient gene highly conserved from
Caenorhabditis elegans to mammals and expressed in
fetal brain. Its function is unknown.
Already the ﬁrst microarray-based analysis of a PTC
gene expression proﬁle (Huang et al. 2001) indicated
the dominant position of genes controlling cell–matrix
adhesion and cell–cell communication. Besides, FN1
mentioned earlier, and intercellular adhesion molecule
1( ICAM-1; Kawai et al. 1998), it seems important to
mention syndecan 4 (SDC4), a transmembrane heparan
sulfate proteoglycan known to bind FN1 and function-
ing also as CXCL12 receptor in signal transduction
(Huang et al. 2001, Chevillard et al. 2004, Finley et al.
2004a). Loss of CDH16 (kidney-speciﬁc cadherin;
Thomson et al. 1998) was indicated for the ﬁrst time in
our study, a gene closely related to cadherin E (CDH1),
which is well known to be lost in a subgroup of PTCs
with negative prognostic signiﬁcance (Rocha et al.
2003), while cadherin P (CDH3) is up-regulated in
PTC (Jarzab et al. 2005). Other genes involved in cell
adhesion and present in our list comprise ectonucleo-
side triphosphate diphosphohydrolase 1 (ENTPD1)
(up-regulated) and less known genes such as NEL-like
2 (up-regulated) and sushi, nidogen, and
EGF-like domains 1 (down-regulated), both exhibiting
EGF-like repeats (Watanabe et al. 1996). The GJB3
gene (connexin 31) encodes the protein subunit of gap
junctions, essential for cell–cell communication.
DPP4 (CD26), ICAM1, and ENTPD1 (CD39) may be
considered as immune-related genes, although their
expression is not conﬁned to immune or endothelial
cells. ICAM1 was shown to be present in thyroid cancer
cells (Kawai et al. 1998). ENTPD1 (ecto-ATPase), in
turn,hasnotbeendescribedbeforeforthethyroidgland;
its expression was shown in some other organs like
salivary glands or exocrine pancreas (Kittel et al. 2004).
It converts adenine nucleotides to adenosine, thus
participating in the control of signal transduction.
DPP4, another membrane-bound enzyme which hydro-
lyzes peptides engaged in paracrine and autocrine
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protein level (Huang et al. 2001, Kholova et al. 2003).
The contribution of various enzymes to our list is
striking:others,notdescribedpreviouslyinthecontextof
thyroid gland, comprise UDP-galactose epimerase
(GALE) and glutaminyl-peptide cyclotransferase
(QPCT), both with virtually unknown expression
patterns. The latter was also indicated by the meta-
analysisofGrifﬁthetal.Amonggeneencodingenzymes
lost in PTC are plasma glutamate carboxypeptidase,
plasma glutamate carboxypeptidase (Gingras et al.
1999),notmentionedinanythyroid-relatedstudybefore;
carbonic anhydrase 4 (CA4), and even the well-known
homogentisate oxidase (encoding HGD), not previously
related to the thyroid in any context, although listed in
many microarray-based reports (Table 1).
Underexpression of hemoglobin transcripts
(HBA1/A2 and HBB scored at positions 2 and 25
respectively) was already discussed in our papers as a
very characteristic feature of PTC gene expression
proﬁle (Jarzab et al. 2005). We believe that the down-
regulation of hemoglobin gene could be associated
with tumor hypoxia; HBA has also been considered a
tumor suppressor since transduction of this gene in an
anaplastic thyroid cancer cell line induces an anti-
proliferative effect (Onda et al. 2005).
Many of the genes listed in Table 1 participate in
signal transduction; among them are MET, ADOR-
A1,RAB27A as well as tumor-associated calcium signal
transducer 2, inositol 1,4,5-triphosphate receptor, type
1( ITPR1), ryanodine receptor 1, all up-regulated in
PTC except for ITPR1. Some enzymes mentioned
above (DPP4, ENTPD1, and QPCT) contribute to
synthesis or breakdown of signaling molecules. On the
other hand, the list also includes many genes
participating in transcription regulation, among them
high-mobility group AT-hook 2, aryl hydrocarbon
receptor, retinoid X receptor, g, ID3, nuclear receptor-
interacting protein 1, and RUNX1. Both of these
functional classes are typical for cancer genes. We
noted only one gene clearly related to apoptosis (and
lost in PTC), the well-known BCL2. Interestingly
enough, some immunohistochemical studies report its
up-regulation in PTC (Aksoy et al. 2005).
Although the selected genes were obtained
by analysis of PTC, many of them may be found
also in other types of thyroid tumors (M Oczko-
Wojciechowska, J Starzyn ´ski, M Jarza ˛b, Z Wygoda,
A Czarniecka, G Gala, M Kalemba, E Gubala &
B Jarza ˛b, unpublished data). This is convincingly
illustrated by the overlapping results of our analysis
and one of the studies which dealt with follicular
thyroid tumors only (Barden et al. 2003).
Accuracy of discriminating PTC from
benign/normal thyroid tissue
Our study is the ﬁrst to deﬁne the classiﬁcation
accuracy for thyroid cancer by 95% CIs and one of
the few dealing with the problem of diagnostic
accuracy of microarray-derived classiﬁers (Kerr &
Churchill 2001). Although the estimation of CIs by
Monte Carlo analysis has not gained a general
acceptance still, it is necessary to stress the very
good accuracy of PTC diagnosis in our study with the
lower range of the CI at 95%, obtained using a
sufﬁciently large study group, mimicking the real
clinical setting. From a clinical point of view, for a
PTC classiﬁer, an even higher accuracy is required, as
the risk of diagnosing PTC in a thyroid nodule is only
about 5% (Hegedus 2004).
Our results stress the importance of multi-gene
approaches for the molecular diagnosis of cancer.
We observed that lower limits of accuracy CIs were
decreased in case of classiﬁcation by gene sets with
less than ten genes. The initial conclusion from these
data is that any combination of more than ﬁve to ten
genes increases the reliability of distinguishing
between malignant and benign tissue samples. This
result is similar to that obtained by Hua et al. (2005),
who demonstrated on simulated and real breast cancer
data that for different classiﬁers the number offeatures
lower than ﬁve was usually much less effective than
larger classiﬁers. Recent paper reports a six-gene
molecular classiﬁer, efﬁcient for molecular diagnosis
of thyroid cancer (Kebebew et al. 2006).
Bootstrap-based multi-gene classiﬁcation of PTC
microarray data
Selection of genes is an important goal of microarray
studies contributing to broader understanding of the
cancertranscriptomeaswellasyieldingnovelmolecular
cancer markers. Such studies have been successfully
performed in PTC and large numbers of discriminating
physiologically relevant genes were proposed (Huang
et al. 2001, Wasenius et al. 2003, Aldred et al. 2004,
Chevillardetal.2004,Finley etal.2004a,b,Wreesmann
et al. 2004, Baris et al. 2005, Detours et al. 2005,
Giordano et al. 2005). However, in the majority of these
studies, the selection of important genes was based on
eitherfold-change orsigniﬁcance criteriaobtainedusing
classical statistical tests. These approaches either favor
genes with large amplitudes, sometimes coming from a
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group variance, thus rather stably expressed in all
analyzed tumor samples. Bearing in mind, complexity
of molecular changes in tumors, the widespread
skepticism about a single ‘cancer marker’ as well as
possible differences in histological subtypes or other
features of PTC, we decided to use SVM, a routine
machine-learningapproachtoconstruct classiﬁers based
onmultiplefeaturesoftheanalyzedobjects.Thismethod
allowsintegratingtheinformationcarriedbymanygenes
in the gene sets. Thus, effective molecular multi-gene
classiﬁers may be built that rely on inter-gene
interactions rather than on combining single ‘best
markers’. SVMs have been conﬁrmed as an effective
method of multi-gene set selection and this is supported
byourcomparisontootherclasspredictionmethods.Our
procedure helps us to optimize the list of markers which
are to be implemented to real-time quantitative PCR-
supported ﬁne needle biopsy (Lubitz & Fahey 2006).
From the diagnostic point of view, the major
drawback of the SVM-based methods are the
ﬂuctuations of gene content between classiﬁers of
different size or based on slightly different training
sets. To overcome this problem, we extended the
original algorithm with bootstrap iterations, as
recommended (Braga-Neto & Dougherty 2004).
A bootstrap iteration depends on creating a temporary
learning set (bootstrap sample) by performing selec-
tion from the original set with return of samples.
Then, the classiﬁcation rule is derived based on a
bootstrap sample and applied to the rest of the original
set. Multiple selections of slightly different training
sets represent the variability, which may be observed
between different thyroid cancer collections, labora-
tories, etc. Indeed, our current data generated using
the bootstrap technique show much better agreement
with the results of other thyroid cancer studies
(Oczko-Wojciechowska et al. submitted) than data
created by leave-one-out cross-validation of the whole
dataset (Jarzab et al. 2005).
Originally,ina bootstrapiterationonecountsonlythe
number of misclassiﬁcations. Since in all bootstrap
iterations every step of data processing (gene selection
and classiﬁer training) has to be repeated (Simon et al.
2003), some additional knowledge can be gained. The
procedureusedbyusenablesrankingofgeneswhichare
most often present in the classiﬁers obtained from the
differentsubsetsofthetrainingset(BBFR).Furthermore,
it also estimates the accuracy with appropriate CIs.
Moreover,itallowsrankingthesamplesaccordingtothe
frequency of misclassiﬁcations (BBOD). The use of
BBFRresultedindelineationofgenes,whichwereeither
novel or not recognized before for their contribution to
the PTC gene expression proﬁle, even if they were
includedinthelargegenelistsgiveninpreviousgenomic
studies. BBOD allowed us to reveal ‘difﬁcult’ samples
in the analyzed group. The two thyroid samples with the
poorestaccuracyofdiagnosiswerederivedfrompatients
with familial thyroid tumors, which suggest that
their gene expression proﬁles may differ from sporadic
ones. For the remaining samples, in 175 out of
180 cases (O97%) the percentage of correct diagnoses
was O90%.
Recently, Zhang et al. (2006) have published a SVM-
based recursive method of gene selection. This method,
called R-SVM,differsfromthe standardRFEalgorithm,
used here, in modiﬁed criteria applied in elimination
steps. Moreover, the ﬁnal gene subset is created on the
basisofanyresamplemethodusedatthevalidationstage,
which is similar to our approach presented here.
Nevertheless,ourbootstrap-basedmethodallowsdetect-
ingoutliersamplesandprovidestheestimationofCIsfor
the classiﬁcation accuracy, which is much more
informative than the accuracy estimator alone.
PTC and normal/benign difference versus
inter-platform difference
To assure a sufﬁcient number of tissue samples, it was
necessary to combine data obtained using different
generations of GeneChips, which cannot be compared
by a direct approach (Eszlinger et al. 2006). The use of
multi-gene classiﬁers allows, however, overcoming
this difﬁculty. We showed earlier that the classiﬁer
selected using the U133 platform (Jarzab et al. 2005)
performs well on U95-obtained data and has high
classiﬁcation accuracy (Eszlinger et al. 2006). In the
present paper, we demonstrate that it is possible, after
correctly matching genes from two different generation
microarrays, to derive an efﬁcient multi-gene classiﬁer.
When we included both benign and malignant samples
from both platforms, the vast majority of these samples
were properly classiﬁed. Using Affymetrix GeneChips,
Barden et al. (2003) and Finley et al. (2004a,b) had
previously reported 20 of 43 genes now conﬁrmed by
us as diagnostically relevant for PTC. This is a level of
agreement rarely noted for inter-group comparisons of
microarray results.
Our analysis has been performed on microarray data
pre-processed by the standard MAS5 algorithm.
Although many authors demonstrate the superiority
of other pre-processing methods (e.g. RMA or
GC-RMA; Irizarry et al. 2003), for inter-platform
comparisons, the MAS5 method still seems to be a
reasonable approach. In the MAS5 algorithm, each
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procedure does not have to involve this step. Use of
RMA pre-processing, which has to operate on the
whole dataset, would pose the question of whether this
step should also be bootstrapped. Presently, this is not
feasible due to huge computational demand of pre-
processing for large sample sets.
Redundancy of multi-gene cancer classiﬁers
This is inherently linked to the huge differences in
gene expression proﬁles of several tumors, originating
from the same tissue. This was indicated for the ﬁrst
time by Ein-Dor et al. (2005) in breast cancer. These
authors re-analyzed the data of van’t Veer et al.
(2002) and showed that multiple similar classiﬁers
may be obtained; they have comparable classiﬁcation
potency as van’t Veer’s original 70-gene classiﬁer but
a different gene content. Ein-Dor et al. stressed also
that even slight differences in the training set
composition inﬂuenced the selected genes. Our
analysis demonstrates that similar redundancy is
present in PTC. This fact is frequently overlooked
by authors interpreting the results of gene expression
proﬁle studies that involved only a few genes or
which were obtained in small groups of patients. In
this paper, we propose a method of ranking genes
according to their importance in multi-gene classiﬁers
and with appropriate CIs indicating the robustness of
the result.
To conclude, the primary goal of this study was to
validate a novel SVM-based approach to differen-
tiation of PTC from benign thyroid lesions. This goal
was achieved with a very satisfactory degree of
accuracy, over 95%. Simultaneously, we were able to
rank the genes most essential for the molecular
diagnosis of PTC. Although the presented list of
genes can be enlarged, we believe the ﬁrst 40 genes
are especially suitable for further prospective studies
i nﬁ n en e e d l eb i o p s ym a t e r i a la n dm a ys e r v et o
construct multi-gene classiﬁers with potential appli-
cation in clinical setting. The comparison with other
published microarray studies yields sufﬁcient vali-
dation for the vast majority of them.
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